Beyond Patents: Assessing the Value and Impact of Research Investments Proceedings of a Workshop–in Brief (2017) / Chapter Skim
Currently Skimming:
Beyond Patents: Assessing the Value and Impact of Research Investments: Proceedings of a Workshop - in Brief
Beyond Patents: Assessing the Value and Impact of Research Investments: Proceedings of a Workshop - in Brief
Pages 1-10
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 1... ...
On June 27 and 28, 2017, the Government-University-Industry Research Roundtable held a meeting to explore these issues. The keynote presentation on June 27 was given by Anne Marie Knott of Olin Business School at Washington University in St.
|
From page 2... ...
Since its creation in 2007, the GII has become one of the leading resources people point to when talking internationally about innovation," Escalona Reynoso stated. Escalona Reynoso described the data sources used and the architecture of the index, which has seven pillars: five innovation inputs: institutions, human capital and research, infrastructure, market sophistication, and business sophistication; and two outputs: creative outputs and knowledge and technology outputs.
|
From page 3... ...
The 2018 Indicators will include intangible capital -- computer software, R&D expenditures, human capital, and freely available knowledge. Also included are data on employment growth, the creation of new firms, multifactor productivity growth, and other data on the impacts of innovation.
|
From page 4... ...
WHERE DO PATENTS FALL SHORT AS A METRIC FOR ASSESSING RESEARCH IMPACTS? The next presentation was given by Petra Moser of the Stem School of Business at New York University, who spoke about patents and innovation in economic history.
|
From page 5... ...
"Sixty years of research suggest that in pharmaceuticals, patents serve as an inducement to innovation, and the propensity to patent important inventions is high." However, Sampat also noted that life sciences innovation is broader than pharmaceuticals, and even in pharmaceuticals, patents miss a lot of the story. "There is a lot more drug patenting than drug innovation, and there is no real correlation over time between patenting and drug innovation.
|
From page 6... ...
They found that a corporate publication is six times more likely to be cited by a patent than a university publication, and that corporate scientific publications have many users, including other companies, universities, and governments. Arora and his colleagues have also found that large firms are investing less in science, and that the stock market value of research is declining.
|
From page 7... ...
"So we came together and wrote our manifesto for the application of metrics to research evaluation, which Nature published about 2 years ago." Hicks showed a video overview of the manifesto, which offers a road map to guide researchers and evaluators toward best practices for measuring research quality -- using quantitative evaluation to support rather than substitute for expert assessment, for example, and measuring performance in accordance with the research missions of the institution (Figure 3)
|
From page 8... ...
Over 7,000 impact case studies were assessed." Hicks continued, "The United Kingdom uses the results of this assessment to help distribute core funding to their universities. Overall, the 7,000 cases are providing a way forward in terms of looking at societal outcomes and getting beyond the narrow view provided by patents." She concluded that the approach is beneficial for universities, which can put the case studies on their websites and make a case to the public about the value their research is providing.
|
From page 9... ...
In addition, it is responsible for operating scientific user facilities, including 10 of DOE's 17 national laboratories. By contrast, in the energy technology offices the set of mission responsibilities is very different -- delivering results on the energy part of DOE's mission, advancing techno-economic goals for energy technologies (e.g., reducing costs, advancing technologies)
|
From page 10... ...
The statements made are those of the author or individual meeting participants and do not necessarily represent the views of all meeting participants, the planning committee, or the National Academies of Sciences, Engineering, and Medicine. REVIEWERS: To ensure that it meets institutional standards for quality and objectivity, this Proceedings of a Workshop -- in Brief was reviewed Gretchen Baier, Dow Chemical Company and Soumitra Dutta, Cornell University.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.